Protease inhibitor-associated angiolipomatosis

被引:19
|
作者
Dank, JP [1 ]
Colven, R [1 ]
机构
[1] Univ Washington, Harborview Med Ctr, Dept Med, Div Dermatol, Seattle, WA 98104 USA
关键词
D O I
10.1016/S0190-9622(00)90021-5
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Treatment with protease inhibitors in some persons infected with HIV-1 is associated with a syndrome of lipodystrophy manifesting as peripheral lipoatrophy, relative central adiposity, insulin resistance, and serum lipid abnormalities. We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir. The mechanism behind this observation may be similar to that of previously reported protease inhibitor-associated fat redistribution, but instead involving the adipose tissue of discrete uncommon benign tumors.
引用
收藏
页码:129 / 131
页数:3
相关论文
共 50 条
  • [1] Protease inhibitor-associated hyperinsulinaemia
    Martínez, E
    Casamitjana, R
    Conget, I
    Gatell, JM
    AIDS, 1998, 12 (15) : 2077 - 2079
  • [2] Protease inhibitor-associated hyperglycaemia
    Dube, MP
    Johnson, DL
    Currier, JS
    Leedom, JM
    LANCET, 1997, 350 (9079): : 713 - 714
  • [3] Management of protease inhibitor-associated hyperlipidemia
    Penzak S.R.
    Chuck S.K.
    American Journal of Cardiovascular Drugs, 2002, 2 (2) : 91 - 106
  • [4] Management of protease inhibitor-associated diarrhea
    Sherman, DS
    Fish, DN
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (06) : 908 - 914
  • [5] Predictors of protease inhibitor-associated adverse events
    Bonfanti, P
    Ricci, E
    Landonio, S
    Valsecchi, L
    Timillero, L
    Faggion, I
    Quirino, T
    BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (06) : 321 - 323
  • [6] Protease Inhibitor-Associated QT Interval Prolongation
    Hunt, Kimberley
    Hughes, Christine A.
    Hills-Nieminen, Cara
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (12) : 1544 - 1550
  • [8] Insulin resistance in HIV protease inhibitor-associated diabetes
    Yarasheski, KE
    Tebas, P
    Sigmund, C
    Dagogo-Jack, S
    Bohrer, A
    Turk, J
    Halban, PA
    Cryer, PE
    Powderly, WG
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 209 - 216
  • [9] Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities
    Thomas, JC
    Lopes-Virella, MF
    Del Bene, VE
    Cerveny, JD
    Taylor, KB
    McWhorter, LS
    Bultemeier, NC
    PHARMACOTHERAPY, 2000, 20 (06): : 727 - 734
  • [10] Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection
    Palma-Aguirre, A
    Halabe-Cherem, J
    Nellen-Hummel, H
    Aburto-Mejía, E
    Ibarra-Herrera, E
    Ponce-Monter, H
    ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (01): : 81 - 84